Bio-Rad Laboratories, Inc. (BIO) Q1 2023 Earnings Results

Bio Rad Laboratories Beats on EPS, Stock Down 0.27%

Bio Rad Laboratories reported a positive surprise in EPS, indicating better-than-expected profitability. However, the stock reacted negatively, declining by 0.27%. This could reflect investor concerns about the lack of revenue details and future guidance, which are critical for assessing the company's growth prospects.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$3.34	N/A	+3.25%
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Cautiously Optimistic

Overall, management conveyed a cautious optimism regarding the company’s performance. They acknowledged market challenges but emphasized their commitment to growth.

Management expressed satisfaction with the EPS performance despite not providing revenue figures.

They highlighted ongoing challenges in the market but remain focused on long-term growth.

Bio Rad Laboratories Beats on EPS, Stock Down 0.27%

Key numbers

Management commentary

Bio-Rad Laboratories, Inc.

More earnings this week

Bio Rad Laboratories Beats on EPS, Stock Down 0.27%

Key numbers

Management commentary